1. Home
  2. CSTE vs ALXO Comparison

CSTE vs ALXO Comparison

Compare CSTE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CSTE

Caesarstone Ltd.

HOLD

Current Price

$1.86

Market Cap

61.9M

Sector

Industrials

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.45

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTE
ALXO
Founded
1987
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.9M
79.7M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
CSTE
ALXO
Price
$1.86
$1.45
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$5.00
$3.30
AVG Volume (30 Days)
536.2K
279.7K
Earning Date
11-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$400,656,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$0.40
52 Week High
$5.04
$2.27

Technical Indicators

Market Signals
Indicator
CSTE
ALXO
Relative Strength Index (RSI) 71.49 51.82
Support Level $0.86 $1.29
Resistance Level $1.94 $1.60
Average True Range (ATR) 0.20 0.13
MACD 0.09 0.01
Stochastic Oscillator 91.73 55.43

Price Performance

Historical Comparison
CSTE
ALXO

About CSTE Caesarstone Ltd.

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: